This "Chronic Rhinosinusitis - Pipeline Insight, 2021" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Rhinosinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinusitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Rhinosinusitis.
Chronic Rhinosinusitis Emerging Drugs Chapters
This segment of the Chronic Rhinosinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Rhinosinusitis Emerging Drugs
CBP-201: Connect Biopharma
CBP-201 is a human monoclonal antibody targeting IL-4R, which we have observed to have dose-dependent and differentiated pharmacokinetics and pharmacodynamics in an early clinical trial. Preclinical and clinical data demonstrate that dual inhibition of IL-4 and IL-13 dual is required to achieve desired efficacy in Th2-mediated diseases. CBP-201 binds to IL-4R in a manner that prevents the receptor from interacting with other receptor subunits that are required for activation of the signaling pathways that ultimately give rise to Th2-mediated diseases, including atopic dermatitis, asthma and nasal polyps. Currently, it is in Phase II stage of clinical trial evaluation to treat Chronic Rhinosinusitis With Nasal Polyps
LYR-210: Lyra Therapeutics
Lyra's lead product candidate, LYR-210, has completed Phase 2 clinical development to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra's XTreoT platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.
Chronic Rhinosinusitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Rhinosinusitis drugs segregated based on following parameters that define the scope of the report.
Major Players in Chronic Rhinosinusitis
There are approx. 6+ key companies which are developing the therapies for Chronic Rhinosinusitis. The companies which have their Chronic Rhinosinusitis drug candidates in the most advanced stage, i.e. phase II include, Lyra Therapeutics.
Key Questions Answered
How many companies are developing Chronic Rhinosinusitis drugs?
How many Chronic Rhinosinusitis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinusitis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinusitis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Rhinosinusitis and their status?
What are the key designations that have been granted to the emerging drugs?
Sanotize Research and Development corp.
Kyowa Kirin Co., Ltd.
Keymed Biosciences Co.Ltd
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/fn74dm
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005682/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900